Format

Send to

Choose Destination
J Oncol. 2009;2009:567486. doi: 10.1155/2009/567486. Epub 2009 May 6.

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.

Author information

1
Division of Hematology and Medical Oncology, J. G. Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.

Abstract

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center